1. Introduction

The tax treatment of biotechnology companies refers to the legal principles governing taxation of businesses engaged in biotechnology research, genetic engineering, pharmaceuticals, vaccine development, agricultural biotechnology, bioinformatics, stem-cell research, diagnostics, synthetic biology and other life-science activities.

Biotechnology companies have distinctive tax issues because their operations frequently involve:

High expenditure on scientific research and development (R&D).

Acquisition and licensing of patents and intellectual property.

Clinical trials and regulatory approvals.

Government grants and research subsidies.

Import and export of biological materials and laboratory equipment.

Commercialisation of genetic technologies and pharmaceutical products.

Cross-border licensing, royalties and technology transfers.

In India, biotechnology companies are principally governed by the Income-tax Act, 1961, the applicable tax rules, the GST framework, customs legislation and relevant international tax treaties.

The central legal challenge is to balance tax collection with incentives for scientific innovation, investment, public health and technological development.

2. Legal Framework Governing Biotechnology Taxation in India

The principal statutory provisions include:

Important: Tax benefits are not automatically available merely because a company operates in biotechnology. Each benefit depends on its statutory eligibility, applicable assessment year, approvals and compliance requirements.

3. Tax Treatment of Research and Development Expenditure

R&D is one of the most important tax-related areas for biotechnology companies.

Typical qualifying activities include:

Development of new vaccines and medicines.

Genetic modification and genome-editing research.

Development of diagnostic technologies.

Research into stem-cell therapies.

Agricultural biotechnology and genetically modified seeds.

Development of biological manufacturing processes.

Relevant law: Section 45 of the Income-tax Act, 2025

From 1 April 2026, the Income-tax Act, 2025 replaces the Income-tax Act, 1961. Section 45 deals with expenditure on scientific research.

It provides for deductions concerning qualifying capital and revenue expenditure on scientific research related to the taxpayer's business, subject to statutory conditions.

It also provides a specific framework for companies engaged in biotechnology and qualifying manufacturing activities with approved in-house R&D facilities. Land acquisition is excluded from the relevant scientific research deduction.

For pharmaceutical and drug companies, qualifying scientific research can include:

Clinical drug trials.

Obtaining regulatory approvals.

Filing patent applications.

The former Section 35(2AB) framework generally allowed a deduction equal to the actual expenditure for relevant expenditure incurred from 1 April 2020 onwards, rather than the earlier weighted deduction.

The new Section 45 should be applied to expenditure falling within the new Act's effective period. Earlier assessment years remain governed by the applicable provisions of the 1961 Act.

IndiaCode+1

Example:

Suppose a biotechnology company spends ₹2 crore on qualifying scientific research during a tax year.

If the entire expenditure qualifies for a 100% deduction, the company can claim ₹2 crore as a deduction, subject to the applicable statutory requirements.

It cannot automatically claim a double deduction simply because it is a biotechnology company.

4. Tax Treatment of Laboratory Equipment and Capital Assets

Biotechnology companies frequently invest in expensive scientific infrastructure.

Examples include:

DNA sequencing machines.

PCR equipment.

Bioreactors.

Laboratory testing instruments.

Refrigeration and biological storage systems.

Pharmaceutical manufacturing machinery.

Computer systems used for bioinformatics.

Relevant law: Section 32 of the Income-tax Act, 1961, and corresponding provisions of the Income-tax Act, 2025.

Depreciation may be claimed on eligible tangible and intangible assets used for business purposes.

The company must establish:

Ownership or qualifying rights over the asset.

Business use of the asset.

Correct classification of the asset.

Compliance with applicable depreciation rates and documentation requirements.

A significant issue arises where equipment is used partly for scientific research and partly for commercial manufacturing. The company must correctly allocate expenditure and avoid claiming the same expenditure twice under different provisions.

5. Tax Treatment of Patents and Biotechnology Intellectual Property

Intellectual property is a major commercial asset for biotechnology companies.

Examples include:

Patents for genetic engineering technologies.

Pharmaceutical formulations.

Vaccine technologies.

Proprietary biological manufacturing processes.

Bioinformatics software.

Licensing rights for diagnostic methods.

Tax treatment depends on whether the company develops, purchases, licenses or sells the intellectual property.

A. Patent acquisition

A patent acquired for business use may qualify as an intangible asset eligible for depreciation, subject to applicable statutory conditions.

B. Royalty income

Where a biotechnology company licenses its patents or technology, the resulting royalty income must be classified under the appropriate income-tax provisions.

C. Patent sale

The sale of a patent may generate business income or capital gains depending on the nature of the asset, its use and the circumstances of the transaction.

D. International patent licensing

Where patents are licensed to foreign companies, transfer-pricing provisions and applicable tax treaties become important.

6. Tax Treatment of Government Grants and Research Subsidies

Biotechnology companies may receive financial assistance from:

Department of Biotechnology.

Government research programmes.

State biotechnology missions.

Public research institutions.

Innovation and start-up support programmes.

The tax treatment depends on the purpose and legal conditions of the grant.

For example:

A grant intended to meet operating expenditure may be taxable as business income, depending on the applicable provisions.

A capital subsidy may receive different treatment.

A grant specifically intended to reduce the acquisition cost of an asset may affect its tax cost and depreciation computation.

Companies should maintain separate accounting records for research grants, capital assistance and operating subsidies.

7. Taxation of Biotechnology Start-ups

Biotechnology start-ups often require substantial initial investment and may not generate profits for several years.

The Indian tax framework provides certain benefits to eligible start-ups.

Section 80-IAC of the Income-tax Act, 1961 and its corresponding framework under the 2025 Act

Eligible start-ups may obtain a tax deduction for qualifying profits for the prescribed period, provided they satisfy the statutory requirements.

Relevant considerations include:

Recognition under the applicable start-up framework.

Incorporation within the prescribed period.

Satisfaction of turnover and other eligibility conditions.

Required certification or approval.

Compliance with restrictions on reconstruction and business formation.

A biotechnology company is not automatically eligible merely because its business involves innovation.

8. Corporate Taxation of Biotechnology Companies

Biotechnology companies are generally subject to corporate income taxation.

Their tax liabilities depend on:

Applicable corporate tax regime.

Total taxable income.

Deductible business expenditure.

Depreciation.

Research deductions.

Losses and their permitted carry-forward.

Surcharge and cess, where applicable.

A company may also consider the optional concessional corporate tax regime under Section 115BAA of the former Income-tax Act, 1961, and its corresponding provisions under the new legislation.

The company must compare the concessional rate with the tax deductions and incentives it would surrender by choosing that regime.

9. GST Treatment of Biotechnology Companies

The Goods and Services Tax framework is important because biotechnology companies frequently supply goods and services across state and international borders.

Relevant legislation includes:

Central Goods and Services Tax Act, 2017.

Integrated Goods and Services Tax Act, 2017.

State Goods and Services Tax legislation.

Customs Act, 1962, for relevant imports and exports.

A. GST on biotechnology products

GST may apply to the sale of:

Vaccines.

Diagnostic kits.

Pharmaceutical products.

Laboratory reagents.

Biotechnology equipment.

Genetically engineered agricultural products.

The applicable rate depends on the precise product classification and relevant GST notifications.

B. GST on clinical research services

Clinical research organisations (CROs) may provide research services to pharmaceutical companies and foreign clients.

The GST treatment depends on whether the transaction qualifies as an export of services under Section 2(6) of the IGST Act.

The principal conditions include:

The supplier is located in India.

The recipient is located outside India.

The place of supply is outside India.

Payment is received in convertible foreign exchange or Indian rupees wherever permitted by RBI.

The supplier and recipient are not merely establishments of the same person under the statutory test.

Where these requirements are satisfied, the supply may qualify as an export of services and be treated as a zero-rated supply under Section 16 of the IGST Act.

C. Input tax credit

Biotechnology companies may claim eligible input tax credit on GST paid for business-related purchases, including laboratory supplies, equipment and professional services.

However, the restrictions under Sections 16 and 17 of the CGST Act must be considered.

10. International Taxation and Transfer Pricing

Biotechnology companies frequently operate through international subsidiaries, research partners, licensing arrangements and contract manufacturing agreements.

Common international transactions include:

Patent licensing.

Technology transfers.

Contract research.

Clinical trial services.

Cross-border management services.

Research collaboration agreements.

Supply of biological products.

The transfer-pricing framework requires international transactions between associated enterprises to comply with the arm's-length principle.

For example, an Indian biotechnology company may develop a patented vaccine technology and license it to its foreign subsidiary.

The royalty charged must be commercially justifiable and consistent with applicable transfer-pricing rules.

Other important issues include:

Withholding tax: Payments to foreign patent owners, research consultants and technology licensors may attract withholding tax depending on the character of the payment, domestic law and applicable treaty.

Permanent establishment: A foreign biotechnology company conducting business in India may create a taxable presence under applicable domestic law and treaty provisions.

Double taxation: Tax treaties may provide relief through foreign tax credits or reduced withholding-tax rates.

Documentation: Companies should maintain transfer-pricing reports, inter-company agreements, valuation studies and evidence of the actual services performed.

11. Tax Treatment of Biotechnology Losses

Biotechnology research often involves substantial investment before commercialisation.

A company may experience losses because of:

Long clinical-trial periods.

Regulatory approval delays.

Research failures.

Expensive laboratory infrastructure.

High patent development costs.

Delayed commercial product launches.

Tax laws provide mechanisms for carrying forward and setting off eligible business losses and unabsorbed depreciation.

However, companies must comply with applicable return-filing deadlines, ownership-change restrictions and other statutory conditions.

A particularly important consideration is that a biotechnology company should distinguish between ordinary business losses, capital losses and unabsorbed depreciation.

12. Tax Compliance and Documentation Requirements

Biotechnology companies should implement a structured tax-compliance system.

The absence of adequate documentation may result in deduction disallowances, interest, penalties and litigation.

13. Important Case Laws Relating to Biotechnology Taxation

The following decisions are particularly useful for understanding scientific research deductions, clinical-trial expenditure, depreciation and GST treatment.

Case 1. CIT v. Claris Lifesciences Ltd.

Citation: (2010) 326 ITR 251 (Gujarat High Court).

Legal issue: Whether depreciation on scientific research assets could be claimed after the company had already claimed a deduction under Section 35(2AB).

Principle: The judgment dealt with the relationship between scientific research deductions and depreciation. It is important when considering whether the same expenditure or asset can generate overlapping tax deductions.

Relevance: Biotechnology companies must avoid double deductions and correctly determine the tax treatment of research assets.

Case 2. CIT v. Cadila Healthcare Ltd.

Citation: (2013) 214 Taxman 672 (Gujarat High Court).

Legal issue: Whether clinical-trial expenditure incurred outside an approved in-house R&D facility could qualify for the enhanced deduction under Section 35(2AB).

Decision: The Gujarat High Court upheld the Tribunal's approach that research conducted using the company's own staff and resources could be considered in-house research, even where clinical trials were conducted outside the physical approved facility.

Relevance: This case is particularly important for pharmaceutical and biotechnology businesses conducting clinical trials through external locations.

However, its application must be considered in light of the statutory requirements and subsequent litigation.

Indian Kanoon+1

Case 3. Principal Commissioner of Income Tax v. Sun Pharmaceuticals Industries Ltd.

Citation: Supreme Court, Civil Appeal No. 2269 of 2025, order dated 11 February 2025.

Legal issue: Whether clinical-trial expenses incurred outside the approved facility could qualify for deduction under Section 35(2AB).

Decision: The Supreme Court remanded the limited issue to the Gujarat High Court for reconsideration alongside the pending Cadila Healthcare litigation.

Legal significance: The Supreme Court did not finally settle the substantive question. The decision demonstrates the importance of distinguishing expenditure incurred inside an approved R&D facility from expenditure incurred externally.

Relevance: Biotechnology companies should not treat the Cadila decision as an unconditional exemption for every outsourced clinical-trial expense.

Sci API

Case 4. M/s Cliantha Research Ltd. – GST Advance Ruling

Authority: Maharashtra Authority for Advance Ruling, Order No. GST-ARA-119/2018-19/B-50, dated 4 May 2019.

Legal issue: Whether clinical research services provided to entities located outside India qualify as exports of services under the IGST Act.

Legal significance: The ruling examined the GST classification of cross-border clinical research services and the statutory export-of-service requirements.

Relevance: It is important for Indian CROs and biotechnology companies providing international research services.

An advance ruling is subject to its statutory binding effect under Section 103 of the CGST Act and should not be treated as universally binding on all taxpayers.

Goods and Services Tax Council+1

14. Important Judicial Principles for Biotechnology Taxation

Indian courts have developed several principles relevant to biotechnology businesses:

Substance over form: Tax treatment should reflect the real nature of the transaction rather than merely its accounting description.

No double deduction: The same expenditure cannot ordinarily be deducted twice under different provisions.

Scientific research versus commercial activity: Genuine scientific investigation must be distinguished from routine quality control, market research and ordinary commercial operations.

Approval requirements: Statutory approval and prescribed documentation are important when claiming research-related deductions.

Cross-border commercial reality: International royalties and research payments must be examined according to their actual contractual and economic substance.

15. Important Challenges in Biotechnology Taxation

Several emerging issues require further legal and regulatory attention.

A. Genetic research taxation

The tax classification of expenditure on genome sequencing, CRISPR research and synthetic biology may create disputes over whether an activity qualifies as scientific research or ordinary commercial expenditure.

B. Artificial intelligence and biotechnology

Companies using AI for drug discovery and genetic diagnostics must distinguish research expenditure from routine software subscriptions, commercial services and technology acquisition.

C. Biological intellectual property

Valuation of patents, genetic technologies and proprietary biological processes creates complex questions concerning depreciation, royalty taxation and transfer pricing.

D. Cross-border research

International research collaborations create issues involving withholding taxes, GST export classification, treaty benefits and permanent establishment.

E. Public-interest biotechnology

Tax incentives for vaccine development, affordable diagnostics and agricultural biotechnology raise questions about how fiscal policy can encourage socially beneficial innovation.

16. Suggestions for Improving the Indian Tax Framework

The following reforms could improve biotechnology taxation:

Introduce clearer guidance for AI-assisted scientific research expenditure.

Improve tax treatment guidance for outsourced clinical trials.

Simplify approval procedures for eligible R&D facilities.

Provide greater certainty concerning government research grants.

Develop clear valuation standards for biotechnology intellectual property.

Improve GST guidance for cross-border clinical research.

Encourage investment in affordable vaccines and diagnostic technologies.

Develop specialised tax dispute-resolution mechanisms for scientific industries.

17. Conclusion

Tax treatment of biotechnology companies is an important component of India's innovation and industrial development framework. Biotechnology businesses face distinctive taxation issues involving scientific research, clinical trials, patents, royalties, laboratory infrastructure, government subsidies, GST and international transactions.

The Income-tax Act, 2025, effective from 1 April 2026, introduces a reorganised statutory framework, including Section 45 for scientific research expenditure. The corresponding Income-tax Rules, 2026 establish approval and compliance procedures for qualifying research facilities.

Judicial decisions such as Claris Lifesciences, Cadila Healthcare and the Supreme Court's 2025 order in Sun Pharmaceuticals Industries demonstrate the importance of interpreting research deductions carefully.

Ultimately, an effective biotechnology tax regime must achieve three objectives: encourage scientific innovation, ensure fair taxation and protect public economic interests.

18. Important Legal References and Research Sources

Income-tax Act, 2025 – Official consolidated legislation.

Section 45 – Scientific research expenditure.

Income-tax Rules, 2026 – Rule 29.

CIT v. Cadila Healthcare Ltd..

PCIT v. Sun Pharmaceuticals Industries Ltd. – Supreme Court order.

Cliantha Research Ltd. – GST advance ruling.

Academic research note: The older case laws under Sections 32 and 35 of the Income-tax Act, 1961 remain relevant for the corresponding principles and transitional assessment years. For expenditure incurred from 1 April 2026, the new Act and Rules must be examined directly rather than assuming that every former provision continues unchanged. Also, the Claris Lifesciences judgment is relevant to the interpretation of R&D facility approval and weighted deduction under the former Section 35(2AB), not a general authority for claiming depreciation on the same research expenditure.